Human ips cell bank for cardiac therapy and drug discovery
Sapphiros AiBio offers a comprehensive biobank of over 85,000 human cell lines, including specialized cardiomyopathy and Long QT syndrome lines, for use in cardiac therapy development and drug discovery. Our iPSC-derived cardiomyocytes are consented for commercial collaborations.
Overview
Sapphiros AiBio presents an extensive biobank of over 85,000 fully consented human cell lines, specifically designed to accelerate therapeutic and drug discovery programs targeting cardiac conditions. Our collection includes lines from patients with cardiomyopathy and Long QT syndrome, fully differentiated into cardiomyocytes. This resource is invaluable for developing cardiac cell therapies and testing drug efficacy and safety.
Technical specifications
Key features:
- Over 85,000 fully consented human cell lines available for commercial and research collaboration.
- Specialized lines include dozens of patient samples with Long QT syndrome and other cardiomyopathies.
- Established protocols for differentiating human induced pluripotent stem cells (iPSCs) into cardiomyocytes.
- Extensive patent portfolio covering human-derived cell therapy technologies.
- Previously collaborated with Harvard Medical School and Mass General Hospital on cardiac cell therapy research.
Technology readiness level
This technology is at TRL 6, indicating a prototype system validated in a relevant environment. Our biobank is ready for collaborative efforts in cardiac therapy development and drug discovery.
About Sapphiros AiBio
Sapphiros AI Bio is a biotechnology research company focused on the field of regenerative medicine and allogeneic cell therapy. The organization utilizes a proprietary biobank containing over 85,000 fully consented human donor cell lines to research and develop therapies aimed at tissue repair, with an initial therapeutic program dedicated to regenerating damaged cartilage. Its platform integrates molecular biology and informatics to model diseases, generate human tissues, and engineer human cells, bridging the gap between research and clinical application.
The company's work in regenerative medicine addresses the need for effective, off-the-shelf therapeutic treatments for various indications and conditions. By leveraging its vast array of genetic variations in its cell bank, Sapphiros AI Bio aims to advance the understanding of human biology and disease to impact healthcare outcomes. While the company is involved in ongoing preclinical development and research, it operates as a distinct entity from the consumer diagnostics platform company Sapphiros.
delivered to your inbox.